Q-omics provides the consensus-scored KRT18P58 profile across patient tissues and cancer cell-line models. KRT18P58 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, KRT18P58 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, KRT18P58 RNA expression shows 8,069 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, LUAD, and THYM as cancer lineages where KRT18P58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P58 survival associations across molecular data types. KRT18P58 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P58 RNA expression–survival associations across cancer types. High KRT18P58 expression shows unfavorable associations in CHOL, LUSC, TGCT, LGG, KIRP and ESCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for KRT18P58 RNA expression.
This table summarizes KRT18P58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P58 shows higher tumor expression in LUAD, STAD, KIRC, BLCA, COAD and BRCA. The LUAD box plot shows higher KRT18P58 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with KRT18P58 in patient tissues and cancer cell lines. In patient samples, KRT18P58 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
